lopinavir has been researched along with Cardiotoxicity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, N; Chen, Z; Gong, J; Gu, S; Huang, ZP; Liu, G; Luo, G; Nie, Y; Wan, Z; Wang, Y; Xu, H; Yang, P; Zhang, D; Zhang, Y | 1 |
| Drici, MD; Fresse, A; Gérard, A; Lepelley, M; Rocher, F; Romani, S; Salem, JE; Viard, D | 1 |
2 other study(ies) available for lopinavir and Cardiotoxicity
| Article | Year |
|---|---|
Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues.
Topics: Antiviral Agents; Calcium; Cardiotoxicity; COVID-19 Drug Treatment; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Induced Pluripotent Stem Cells; Lopinavir; Myocytes, Cardiac; Pluripotent Stem Cells; Quetiapine Fumarate; Ritonavir | 2022 |
Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.
Topics: Aged; Aged, 80 and over; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Electrocardiography; Female; France; HIV Protease Inhibitors; Humans; Long QT Syndrome; Lopinavir; Male; Middle Aged; Pharmacovigilance; Potassium Channel Blockers; Ritonavir | 2021 |